FIELD: medicine; neurology.
SUBSTANCE: individuals susceptible to eicosapentaenoic acid (EPA) treatment are identified by defining of CAG repetition number in Huntingtin gene within 36-45. To prevent and heal Huntington's disease (HD) symptom development, the persons with CAG repetition number within 36 to 45 are administered with EPA in any biologically viable form.
EFFECT: reduced brain tissue loss for patients and prevention of symptom development for persons prone to that; improved treatment results for patients with this genetic disease form.
16 cl, 20 ex
